135 related articles for article (PubMed ID: 28956740)
1. Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.
He Q; Wang HH; Cheng T; Yuan WP; Ma YP; Jiang YP; Ren ZH
Chin Med Sci J; 2017 Sep; 32(3):135-144. PubMed ID: 28956740
[TBL] [Abstract][Full Text] [Related]
2. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
[TBL] [Abstract][Full Text] [Related]
4. Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX.
Ramaswamy S; Tonnu N; Menon T; Lewis BM; Green KT; Wampler D; Monahan PE; Verma IM
Cell Rep; 2018 May; 23(5):1565-1580. PubMed ID: 29719266
[TBL] [Abstract][Full Text] [Related]
5. Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.
Ma Y; Sun W; Zhao L; Yao M; Wu C; Su P; Yang L; Wang G
Stem Cell Res Ther; 2022 Jul; 13(1):353. PubMed ID: 35883203
[TBL] [Abstract][Full Text] [Related]
6. Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA.
Martorell L; Luce E; Vazquez JL; Richaud-Patin Y; Jimenez-Delgado S; Corrales I; Borras N; Casacuberta-Serra S; Weber A; Parra R; Altisent C; Follenzi A; Dubart-Kupperschmitt A; Raya A; Vidal F; Barquinero J
J Thromb Haemost; 2017 Nov; 15(11):2188-2197. PubMed ID: 28834196
[TBL] [Abstract][Full Text] [Related]
7. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte-Like Cells Derived From Mouse Induced Pluripotent Stem Cells Produce Functional Coagulation Factor IX in a Hemophilia B Mouse Model.
Wu YM; Huang YJ; Chen P; Hsu YC; Lin SW; Lai HS; Lee HS
Cell Transplant; 2016; 25(7):1237-46. PubMed ID: 26395869
[TBL] [Abstract][Full Text] [Related]
9. In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.
Luce E; Steichen C; Allouche M; Messina A; Heslan JM; Lambert T; Weber A; Nguyen TH; Christophe O; Dubart-Kupperschmitt A
Hepatology; 2022 Apr; 75(4):866-880. PubMed ID: 34687060
[TBL] [Abstract][Full Text] [Related]
10. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
[TBL] [Abstract][Full Text] [Related]
11. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
Guan Y; Ma Y; Li Q; Sun Z; Ma L; Wu L; Wang L; Zeng L; Shao Y; Chen Y; Ma N; Lu W; Hu K; Han H; Yu Y; Huang Y; Liu M; Li D
EMBO Mol Med; 2016 May; 8(5):477-88. PubMed ID: 26964564
[TBL] [Abstract][Full Text] [Related]
13. Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of
Wang Y; Zhao J; Duan N; Liu W; Zhang Y; Zhou M; Hu Z; Feng M; Liu X; Wu L; Li Z; Liang D
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301136
[TBL] [Abstract][Full Text] [Related]
14. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
[TBL] [Abstract][Full Text] [Related]
15. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
16. Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Park CY; Sung JJ; Cho SR; Kim J; Kim DW
Stem Cell Reports; 2019 Jun; 12(6):1242-1249. PubMed ID: 31105049
[TBL] [Abstract][Full Text] [Related]
17. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
18. The State of Skewed X Chromosome Inactivation is Retained in the Induced Pluripotent Stem Cells from a Female with Hemophilia B.
Lyu C; Shen J; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang D; Zhang X; Cheng T; Yang R; Zhang L
Stem Cells Dev; 2017 Jul; 26(13):1003-1011. PubMed ID: 28401797
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Mediated In Situ Introduction or Integration of
Tang Q; Hu Z; Zhao J; Zhou T; Tang S; Wang P; Xiao R; Chen Y; Wu L; Zhou M; Liang D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240366
[TBL] [Abstract][Full Text] [Related]
20. PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells.
Hiramoto T; Kashiwakura Y; Hayakawa M; Baatartsogt N; Kamoshita N; Abe T; Inaba H; Nishimasu H; Uosaki H; Hanazono Y; Nureki O; Ohmori T
Commun Med (Lond); 2023 Apr; 3(1):56. PubMed ID: 37076593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
